Cirrhosis/Liver Failure News

Alcohol consumption — including light-to-moderate — was associated with an increased risk for hepatocellular carcinoma among patients with hepatitis C virus infection-related cirrhosis, according to published findings.

SAN DIEGO —  Despite increased rates of acetaminophen-induced acute liver injury and acute liver failure than male counterparts, women did not experience poorer survival outcomes related to these conditions, according to findings presented at Digestive Disease Week 2016.

Gastroesophageal variceal bleeding was common in patients with portal vein thrombosis without cirrhosis. The progression of varices at high risk for bleeding were similar to the development of varices in patients with cirrhosis.

Statin use was associated with a decreased risk for developing cirrhosis and decompensation in Taiwanese patients with chronic hepatitis B virus infection, according to published findings.

In a phase 1 clinical trial, cenicriviroc showed favorable pharmacokinetics in patients with mild-to-moderate liver cirrhosis.

The use of a light electroencephalography wireless headset to diagnose and grade hepatic encephalopathy is both reliable and cost-effective compared with standard electroencephalography.

Broad spectrum antibiotic treatment was more effective and improved survival compared with standard therapy in patients with cirrhosis with health care–associated infections, according to new study data published in Hepatology.

Conatus Pharmaceuticals Inc. announced positive results of the second stage of its phase 2 liver cirrhosis clinical trial, indicating emricasan, a pan-caspase inhibitor, improved liver function in patients with various etiologies of cirrhosis.

BARCELONA — Rifaximin was associated with significantly lower disease recurrence and mortality than norfloxacin in a cohort of patients with spontaneous bacterial peritonitis, according to findings presented at the International Liver Congress.

BARCELONA — A new allocation treatment algorithm was effective for predicting benefit and survival rate after treatment for end-stage liver disease when hospitalized, according to findings presented at International Liver Congress.